1Ano·

News: $IBRX (-2,13%) US FDA approves bladder cancer therapy from ImmunityBio!

Very positive for the rest of the pipeline ... lets go!

9 Comentários

PaulPaulsonle@PaulPaulsonle

1Ano

I opened a mini position, I'm very excited

•

Fuchs89@Valuereg

1Ano

a milestone in cancer therapy. I have been invested since 2021 and will hold for a long time

•

Chris Lee@Vestin

1Ano

@nit I am also invested and very confident. Great company and only at the beginning.

•

TrendingRobin@TrendingRobin

1Ano

Also invested since 2021 and looking forward to the development

•

Hugo_Offiziell@_Hugo_

1Ano

You did everything right 👍🏻. Once again, I hesitated too long 🙄

••

PaulPaulsonle@PaulPaulsonle

11Mês

Do any of you know why they have already risen 9% in pre-market trading today?
Greetings

••

Fuchs89@Valuereg

11Mês

@PaulPaulsonle
https://finance.yahoo.com/news/immunitybio-executive-chairman-dr-patrick-120000920.html

Patrick Soon-Shiong will present the implications and results of N-803 (ANKTIVA) at the annual meeting of the AUA (American Urological Association).

••

PaulPaulsonle@PaulPaulsonle

11Mês

Thank you very much👌👌👌👌
I'm currently considering whether I should increase my position by a lot before the stock market opens in America😅
Do you think that's a good idea?

••

Fuchs89@Valuereg

11Mês

@PaulPaulsonle I can't tell you, as I don't have a crystal ball ^^ With a market cap of over 5 billion, a lot of future performance is of course already priced in. Personally, I think that risk/reward is very attractive in both the short and long term. However, you should not rely on other opinions, but do your own research and adjust your position according to your risk management.
(not investment advice)

••